Reported 1 day ago
Novo Nordisk's stock plummeted over 21% after the company downgraded its sales and profit forecasts for its popular weight-loss drug Wegovy and diabetes medication Ozempic, citing intensified competition and weaker-than-expected sales. This marks the second time this year that the company has lowered its expectations, with the stock price now down more than 55% over the past year.
Source: YAHOO